Abstract:612 Background: Pancreatic Adenocarcinoma (PA) is a leading cause of cancer-related death across the world, with poorer outcomes noted in minority populations. The observed variation in outcomes has been attributed to delayed diagnosis, barriers to optimal treatment and health care related disparities. We evaluated the impact of race on clinical presentation and outcomes in pancreatic cancer at a large academic teaching center. Methods: We performed a retrospective review of patients with pancreatic adenocarcinoma diagnosed between January 2016 to December 2021. The demographic characteristics (age, tobacco use, alcohol use, BMI); comorbidities (diabetes, acute/chronic pancreatitis); pathology, treatment (chemotherapy regimen, radiation, surgery) and recurrence free survival (RFS) and overall survival based on race were analyzed. Results: The cohort (N=947) consisted of 147 (16%) African Americans (AA) and 775 (82%) Non-Hispanic Whites (NHW). The mean age at diagnosis was 68 years (±10) among AA and 70 years (±11) in NHW. Thirty-seven (26%) of AA and 104 (14%) of NHW were current smokers; 46 (33%) of AA and 323 (45%) of NHW consumed alcohol regularly. Among AA, 32 (22%) were obese (BMI>30), compared to 194 (25%) in NHW. Other comorbidities included diabetes (35% in AA vs. 32% in NHW) and acute/chronic pancreatitis (11% among AA vs. 9% among NHW). Eighteen percent (18%) of AA and 17% of NHW had stage II disease, 16% and 12% had stage III and 48% in both had stage IV disease respectively. The treatment modality consisted of chemotherapy (63% in AA vs. 66% in NHW), surgery (25% in AA vs. 26% in NHW) and radiation (10% in AA vs. 12% in NHW). The median time to treatment initiation was 30 (17, 41) months for AA and 26 (16, 40) months for NHW. On univariate analysis, AA race was associated with younger age at diagnosis (p 0.043), higher current tobacco use (p 0.001), lower alcohol use (p 0.012), lower rates of obesity (p 0.024) and higher rate of acute pancreatitis (p 0.037) in pancreatic cancer. On multivariate analysis, race was not associated with difference in recurrence free survival (12 months in AA vs. 14 months in NHW; p 0.96) when adjusted for age, sex, alcohol use, tobacco use, cancer stage and chemotherapy. High mean age, clinical stage II, III and IV, current alcohol use, underweight and BMI>30 and cerebrovascular accident as a comorbidity was associated with worse overall survival when adjusted for other variables. Conclusions: Our study revealed that pancreatic cancer in AA was diagnosed at a younger age, associated with active smoking and pancreatitis. We observe there was no difference in treatment initiation among AA and NHW. There was no significant difference in recurrence free survival and overall survival compared to NHW when adjusted for other variables. Future studies incorporating germline mutations, novel biomarkers are needed to determine impact of racial health disparities on outcomes in pancreatic cancer.

S86 Disparities in Acute Pancreatitis-Related Mortality Among Diabetics in the United States

S66 Analysis of Mortality Trends in Acute Pancreatitis in the United States, 1999-2020: An Analysis of CDC WONDER Database

S207 Differences In Clinical Outcomes Between Acute Pancreatitis Caucasian, African American, and Asian Population With Metabolic Dysfunction-Associated Steatotic Liver Disease

S95 Temporal Trends and Regional Differences in Septicemia-Related Mortality in Patients With Acute Pancreatitis: A Two-Decade Analysis From 1999-2020

Favorable Trends in Mortality among Patients with Concomitant Peripheral Arterial Disease and Diabetes Mellitus over Past Two Decades

The Impact of Diabetes on Mortality in Inpatients from Medical Department of A Chinese Tertiary Hospital

S83 Trends in Mortality Due to Pancreatitis Among Patients Aged 55 and Older in the United States: Insights from the CDC WONDER Database

An Observational Study of Socioeconomic and Clinical Gradients among Diabetes Patients Hospitalized for Avoidable Causes: Evidence of Underlying Health Disparities in China?

S134 Demographic Inequalities in Participant Enrollment in Clinical Trials for Acute And Chronic Pancreatitis in the United States

S10 Trends and Disparities in Pancreatic Cancer Mortality in the United States From 1999 to 2020

Clinical Outcomes of Diabetes Mellitus on Moderately Severe Acute Pancreatitis and Severe Acute Pancreatitis

Disparities In Diabetes-Related Lower Extremity Amputations In The United States: A Systematic Review

Diabetes Mellitus and Peripartum Cardiomyopathy: A Nationwide Study

Temporal and regional trends in adults with diabetics kidney disease in the US from 1999 to 2020

Disparities in Pancreatic Cancer Treatment and Outcomes

Abstract TMP103: Trends in Ischemic Stroke-Related Mortality in Patients With Type 2 Diabetes in the United States, 1999-2020

Urban–rural disparities in diabetes-related mortality in the USA 1999–2019

A Systematic Review of Recent Studies on Hospital Readmissions of Patients With Diabetes

Assessing disparities in pancreatic cancer outcomes in African Americans.

S21 Evaluating Disparities in Pancreatic Cancer-Related Mortality Trends: A 20-Year Analysis in the United States vs Texas Using the CDC WONDER Database

Correlation of hyperglycemia and balthazar classification in patients with acute pancreatitis